CHALLENGE-HD
Huntington's Disease

A phase 1/2, two-part, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and pharmacodynamics of SBT-20 in patients with early stage Huntington's disease (HD).

In Western countries, it's estimated that about

5-7 PEOPLE PER 100K ARE AFFECTED BY HD

This study will assess approximately 24 individuals.

Subjects will participate in both Part 1 and Part 2 of the study.

AGES 18+

TRIAL DURATION:

PART 1 - 7 DAYS PART 2 - 28 DAYS

TRIAL BEGAN
Q1 2017

TRIAL SITES

1 trial center

The Netherlands

G.J. (GEERT JAN) GROENEVELD, MD, PHD

ENDPOINTS

PRIMARY

Safety and tolerability

SECONDARY

Investigate the effect of SBT-20 on mitochondrial function

Assess the pharmacokinetics of SBT-20

Stealth BIOTHERAPEUTICS